• Aktuelle Seite:  
  • Home
  • Substitution in Haft
A- A A+

USA. Six Strategies to Prevent MOUD Diversion in Jail-Based Treatment Programs

Diversion of medication for opioid use disorder (MOUD) treatment is often cited as a concern and a reason for not offering the medications in jails and prisons. Researchers from the University of Massachusetts published a study in 2023 that detailed promising practices in program design to help limit medication diversion. The study also details guidance for corrections and lawmakers as they consider implementing MOUD treatment in correctional settings. (Addiction Policy Forum, USA, 07.08.2023)

https://www.addictionpolicy.org/post/six-strategies-to-prevent-moud-diversion-in-jail-based-treatment-programs

Oral health services in prison settings: A global scoping review of availability, accessibility, and model of delivery. 

Amaya, A., Medina, I., Mazzilli, S., D'Arcy, J., Cocco, N., Van Hout, M.-C., Stöver, H., & Moazen, B. (2023). 

Journal of Community Psychology, 1–30. doi.org/10.1002/jcop.23081

https://onlinelibrary.wiley.com/doi/10.1002/jcop.23081

USA. GUIDELINES FOR MANAGING SUBSTANCE WITHDRAWAL IN JAILS

A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals

U.S. Department of Justice, Office of Justice Programs, Juni 2ß23

https://www.cossapresources.org/Content/Documents/JailResources/Guidelines_for_Managing_Substance_Withdrawal_in_Jails_6-6-23_508.pdf

USA.  Underlying Causes of MOUD Diversion in Jails: Strategies and Solutions

Medications for opioid use disorder (MOUD) are the leading evidence-based treatment for opioid use disorder (OUD). Abundant research shows that MOUD reduces the risk of recurrence of opioid use, involvement with the justice system, and death, both in the community and in jails. (PRA – Policy Research Associates, USA, 18.04.2023)

https://www.prainc.com/gains-moud-diversion/

Global Prison Trends 2023

Global Prison Trends 2023 is PRI’s annual flagship report, published with the Thailand Institute of Justice, examining key trends and challenges in prison systems worldwide. (PRI – Penal Reform International, UK/Niederlande, Juni 2023)

https://www.penalreform.org/global-prison-trends-2023/?mc_cid=8fa2233530&mc_eid=b91523d211

Nationale Stelle zur Verhütung von Folter beklagt Missstände im Maßregelvollzug

Berlin – Die Nationale Stelle zur Verhütung von Folter hat anhaltende Missstände in Gefängnissen und Einrichtungen des Maßregelvollzugs in Deutschland beklagt. (aerzteblatt.de, 16.06.2023)

https://www.aerzteblatt.de/nachrichten/143977/Nationale-Stelle-zur-Verhuetung-von-Folter-beklagt-Missstaende-im-Massregelvollzug

Hinter deutschen Gefängnis-Gittern

Mangelnde Behandlung, isolierte Unterbringung, menschenunwürdige Suizidprävention: Die Situation von psychisch kranken Straftätern, die in Gefängnissen einsitzen, ist vielerorts erbärmlich und erinnert an schlimmste Verwahrpsychiatrie, wenn Patienten fast den ganzen Tag eingeschlossen werden und sich psychiatrische Behandlung im Wesentlichen auf Medikamentenvergabe beschränkt. Viele Gründe für die Bildung einer Task-Force, wie sie die DGPPN* im Vorjahr angeschoben hat. Auch der jüngste DGPPN-Kongress diskutierte über „Psychiatrische Versorgung von Haftanstalten“. (Eppendorfer, 31.05.2023)

https://eppendorfer.de/hinter-deutschen-gittern/

Burden of opioid toxicity death in the fentanyl-dominant era for people who experience incarceration in Ontario, Canada, 2015-2020: a whole population retrospective cohort study. 

Butler A, Croxford R, Bodkin C, Akbari H, Bayoumi AM, Bondy SJ, Guenter D, McLeod KE, Gomes T, Kanagalingam T, Kiefer LA, Orkin AM, Owusu-Bempah A, Regenstreif L, Kouyoumdjian F. 

BMJ Open. 2023 May 10;13(5):e071867. doi: 10.1136/bmjopen-2023-071867. PMID: 37164452; PMCID: PMC10186413.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186413/

The role of substance use treatment in reducing stigma after release from incarceration: A qualitative analysis. 

Moore KE, Wyatt JP, Phillips S, Burke C, Bellamy C, McKee SA. 

Health Justice. 2023 May 16;11(1):25. doi: 10.1186/s40352-023-00225-w. PMID: 37191937; PMCID: PMC10186797.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186797/

Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration. 

Cadet T, Jalali A, Jeng PJ, Poole S, Woody G, Murphy SM. 

Addict Sci Clin Pract. 2023 May 25;18(1):34. doi: 10.1186/s13722-023-00375-0. PMID: 37231479; PMCID: PMC10210389.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210389/

Is Providing Medications for Opioid Use Disorder to Incarcerated Individuals a Cost-effective Strategy? 

Bounthavong M. 

JAMA Netw Open. 2023 Apr 3;6(4):e237001. doi: 10.1001/jamanetworkopen.2023.7001. PMID: 37058311.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803902

Incarceration status at buprenorphine initiation and OUD treatment outcomes during pregnancy.

Nguyen A, Shadowen H, Shadowen C, Thakkar B, Knittel AK, Martin CE. 

Front Psychiatry. 2023 Apr 13;14:1157611. doi: 10.3389/fpsyt.2023.1157611. PMID: 37124262; PMCID: PMC10133465.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133465/

Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts. 

Chatterjee A, Weitz M, Savinkina A, Macmadu A, Madushani RWMA, Potee RA, Ryan D, Murphy SM, Walley AY, Linas BP. 

JAMA Netw Open. 2023 Apr 3;6(4):e237036. doi: 10.1001/jamanetworkopen.2023.7036. PMID: 37058306; PMCID: PMC10105308.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105308/

HIV and HCV among drug users and people living in prisons in Germany 2022: WHO elimination targets as reflected in practice. 

Stöver, H., Dichtl, A., Schäffer, D. et al.

Harm Reduct J 20, 50 (2023). https://doi.org/10.1186/s12954-023-00774-1

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-023-00774-1

Health and correctional staff acceptability of depot buprenorphine in NSW prisons. 

Little S, White B, Moensted M, Butler K, Howard M, Roberts J, Dunlop A. 

Int J Drug Policy. 2023 Apr;114:103978. doi: 10.1016/j.drugpo.2023.103978. Epub 2023 Mar 2. PMID: 36870227.

https://www.sciencedirect.com/science/article/pii/S0955395923000270

Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities. 

Ryan DA, Montoya ID, Koutoujian PJ, Siddiqi K, Hayes E, Jeng PJ, Cadet T, McCollister KE, Murphy SM. 

Subst Use Addict Treat. 2023 Mar;146:208943. doi: 10.1016/j.josat.2022.208943. Epub 2023 Jan 26. PMID: 36880906.

https://www.sciencedirect.com/science/article/pii/S2949875922000145

Detection of methadone and buprenorphine in urine samples from inmates of German prisons.

Franchetti G, Thierauf-Emberger A, Franz A, Thoma V, Auwärter V, Huppertz LM. 

Front Psychiatry. 2023 Feb 28;14:1139370. doi: 10.3389/fpsyt.2023.1139370. PMID: 36926464; PMCID: PMC10011066.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011066/

"Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories. 

Hoffman KA, Thompson E, Gaeta Gazzola M, Oberleitner LMS, Eller A, Madden LM, Marcus R, Oberleitner DE, Beitel M, Barry DT. 

Addict Sci Clin Pract. 2023 Mar 21;18(1):16. doi: 10.1186/s13722-023-00377-y. PMID: 36944998; PMCID: PMC10031976.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031976/

Opioid overdose risk 10 times greater for those recently released from prison, research shows

People recently released from prison in Oregon face a risk for opioid overdose 10 times greater than the general public, according to a new study led by an Oregon State University College of Pharmacy scientist.  (MedicalXpress, USA, 08.03.2023)

https://medicalxpress.com/news/2023-03-opioid-overdose-greater-prison.html

Negative attitudes about medications for opioid use disorder among criminal legal staff.

Moore KE, Siebert SL, Kromash R, Owens MD, Allen DC. 

Drug Alcohol Depend Rep. 2022 Apr 25;3:100056. doi: 10.1016/j.dadr.2022.100056. PMID: 36845981; PMCID: PMC9948914.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948914/

Ibrahim A. erstach zwei Jugendliche - "Der Täter von Brokstedt hatte eine Psychose"

Suchtarzt Göran Michaelsen nennt mögliche Gründe für den Ausraster des Messerangreifers von Brokstedt. Er übt außerdem Kritik am Umgang mit Ibrahim A.

Sechs Wochen sind inzwischen vergangen, seit Ibrahim A. in einem Regionalzug von Kiel nach Hamburg zwei Jugendliche mit einem Messer tötete und fünf weitere Menschen verletzte. Dennoch sind noch immer viele Fragen offen – insbesondere das Motiv ist weiter unklar. 

Wie inzwischen bekannt ist, soll der Palästinenser nicht nur an einer schweren Drogenabhängigkeit, sondern auch an episodenhaften Wahnvorstellungen gelitten haben. In diesem Zusammenhang wirft auch seine Methadonbehandlung während der Untersuchungshaft in Hamburg-Billwerder zunehmend Fragen auf. (t-online, 04.03.2023)

https://www.t-online.de/region/hamburg/id_100138126/messerattacke-von-brokstedt-taeter-hatte-eine-psychose-durch-drogen.html

Prospective study of retention in opioid agonist treatment and contact with emergency healthcare following release from prisons in Victoria, Australia. 

Curtis M, Wilkinson AL, Dietze P, Stewart AC, Kinner SA, Cossar RD, Nehme E, Aitken C, Walker S, Butler T, Winter RJ, Smith K, Stoove M. 

Emerg Med J. 2023 Feb 9:emermed-2022-212755. doi: 10.1136/emermed-2022-212755. Epub ahead of print. PMID: 36759173.

https://emj.bmj.com/content/early/2023/02/09/emermed-2022-212755.long

Post-incarceration outcomes of a comprehensive statewide correctional MOUD program: a retrospective cohort study. 

Martin RA, Alexander-Scott N, Berk J, Carpenter RW, Kang A, Hoadley A, Kaplowitz E, Hurley L, Rich JD, Clarke JG. 

Lancet Reg Health Am. 2022 Dec 23;18:100419. doi: 10.1016/j.lana.2022.100419. PMID: 36844014; PMCID: PMC9950664.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950664/

Europa. Status report on prison health in the WHO European Region 2022

This report provides an overview of the performance of prison health systems in the WHO European Region. It contains 2020 data obtained through a survey collected from 36 countries, where a total of 613 497 people were deprived of their liberty. 

(…) The most prevalent condition was mental health disorders, but the ratio of psychiatrists to people in prison did not ensure equity of care and access to treatment was suboptimal. Harm minimization focused mostly on access to drug use treatment and less on safe injecting or tattooing practices. Access to hepatitis C (‎HCV)‎ treatment was not on track to achieve HCV elimination and needs urgent attention. The most common cause of death in prisons was suicide, followed by COVID-19 and drug overdose. Overcrowding was reported in 20% of Member States. (WHO, Genf, 15.02.2023)

https://www.who.int/europe/publications/i/item/9789289058674

Continuity of opioid substitution treatment between prison and community in Southeast Asia: A scoping review. 

Loh DA, Plugge E, Van Hout MC. 

Int J Drug Policy. 2023 Jan 22;112:103957. doi: 10.1016/j.drugpo.2023.103957. Epub ahead of print. PMID: 36693296.

https://www.sciencedirect.com/science/article/pii/S0955395923000063

The predictive validity of the Alcohol Smoking and Substance Involvement Screening Test (ASSIST) for moderate-to-high risk cannabis, methamphetamine and opioid use after release from prison

Cumming, C., Kinner, S. A., McKetin, R., Young, J. T., Li, I., and Preen, D. B. (2023) Addiction. doi: doi.org/10.1111/add.16138.

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.16138?campaign=wolacceptedarticle

Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S.. 

Scott, C.K., Grella, C.E., Dennis, M.L. et al.

Health Justice 10, 36 (2022). doi.org/10.1186/s40352-022-00197-3

https://healthandjusticejournal.biomedcentral.com/articles/10.1186/s40352-022-00197-3

USA. Maine’s Prisons Taught Washington a Crucial Lesson in Fighting Opioids 

Using drugs to treat addicts inside prison might just be the best way to stem the crisis of overdose deaths. (Politico, USA, 08.01.2023)

https://www.politico.com/news/magazine/2023/01/08/maines-prisons-opioids-00076822

USA. Prison “K2”: The Hidden Center of a Chaotic New Drug War

Prison drug supply has been forensically analyzed many times, but never before in collaboration with prisoners instead of law enforcement. (Filter, USA, 28.11.2022)

https://filtermag.org/synthetic-cannabinoids-k2-prison-parole

Discontinuation of opioid agonist treatment following release from prison in a cohort of men who injected drugs prior to imprisonment in Victoria, Australia: A discrete-time survival analysis. 

Curtis M, Dietze P, Wilkinson AL, Agius PA, Stewart AC, Cossar RD, Butler T, Walker S, Kirwan A, Winter RJ, Stoové M. 

Drug Alcohol Depend. 2023 Jan 1;242:109730. doi: 10.1016/j.drugalcdep.2022.109730. Epub 2022 Dec 7. PMID: 36516552.

https://www.sciencedirect.com/science/article/pii/S0376871622004677

  1. Vermeidung drogeninduzierter Mortalität nach Haftentlassung
  2. Deaths in prison: Examining causes, responses, and prevention of deaths in prison worldwide
  3. Non -fatal opioid overdose after release from prison among men who injected drugs prior to their imprisonment: a prospective data linkage study. 
  4. Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model. 
  5. Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia.